Compare REAX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAX | ABUS |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.1M | 888.5M |
| IPO Year | N/A | N/A |
| Metric | REAX | ABUS |
|---|---|---|
| Price | $2.74 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.90 | $5.00 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 03-04-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,813,907,000.00 | $14,606,000.00 |
| Revenue This Year | $57.12 | $125.30 |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 65.60 | ★ 116.64 |
| 52 Week Low | $2.55 | $2.71 |
| 52 Week High | $5.65 | $5.10 |
| Indicator | REAX | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 44.23 |
| Support Level | $2.55 | $3.85 |
| Resistance Level | $3.28 | $4.26 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 16.27 | 46.82 |
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.